Laurus Labs Ltd's Q3FY25 Quarter Results
- 25 Jan 2025
Result Summary
- Laurus Labs Ltd reported a 16.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 19.0%.
- Its expenses for the quarter were up by 7.3% QoQ and 11.3% YoY.
- The net profit increased 365.9% QoQ and increased 298.2% YoY.
- The earnings per share (EPS) of Laurus Labs Ltd stood at 1.7 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1424.47 | 1228.30 | 1197.35 | 16.0% | 19.0% |
Total Expenses | 1293.79 | 1205.49 | 1162.73 | 7.3% | 11.3% |
Profit Before Tax | 130.68 | 22.81 | 34.62 | 472.9% | 277.5% |
Tax | 40.07 | 5.09 | 9.45 | 687.2% | 324.0% |
Profit After Tax | 92.94 | 19.95 | 23.34 | 365.9% | 298.2% |
Earnings Per Share | 1.70 | 0.40 | 0.40 | 325.0% | 325.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Laurus Labs Ltd is a renowned pharmaceutical company headquartered in India. The company is primarily involved in the manufacturing and development of active pharmaceutical ingredients (APIs), formulations, and biotechnology products. Laurus Labs serves a wide range of therapeutic areas including anti-retroviral, oncology, cardiovascular, and anti-diabetics. The company has a significant presence in the global pharmaceutical market, supplying its products to various countries. While specific recent developments are not noted in the provided data, Laurus Labs is known for its commitment to innovation and expansion within the pharmaceutical industry.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Laurus Labs Ltd reported a total income of ₹1424.47 crores. This marks a growth of 16.0% quarter-over-quarter (QoQ) from ₹1228.30 crores in Q2FY25 and a 19.0% year-over-year (YoY) increase from ₹1197.35 crores in Q3FY24. The consistent rise in total income over these periods reflects the company's robust revenue generation capabilities. The increase in revenue, both QoQ and YoY, highlights a period of substantial income growth for the company.
Profitability
Laurus Labs Ltd's profitability in Q3FY25 shows significant improvement. The company recorded a profit before tax of ₹130.68 crores, which is a substantial increase of 472.9% QoQ from ₹22.81 crores in Q2FY25, and a 277.5% increase YoY from ₹34.62 crores in Q3FY24. The profit after tax for Q3FY25 was ₹92.94 crores, up 365.9% QoQ from ₹19.95 crores in Q2FY25 and up 298.2% YoY from ₹23.34 crores in Q3FY24. Earnings per share also saw a considerable increase, recorded at ₹1.70 in Q3FY25, rising 325.0% both QoQ and YoY from ₹0.40 in the previous quarter and the same quarter of the prior year. The substantial rise in profitability metrics indicates enhanced financial performance over the periods.
Operating Metrics
The total expenses for Laurus Labs Ltd in Q3FY25 were reported at ₹1293.79 crores, which denotes a 7.3% increase QoQ from ₹1205.49 crores in Q2FY25 and an 11.3% increase YoY from ₹1162.73 crores in Q3FY24. Despite the rise in total expenses, the company's profit margins improved significantly, as evidenced by the higher profit before and after tax figures. The tax expense for Q3FY25 was ₹40.07 crores, which increased by 687.2% QoQ from ₹5.09 crores in Q2FY25 and 324.0% YoY from ₹9.45 crores in Q3FY24. This suggests that the company faced higher tax liabilities due to increased profits. The financial data reflects strong operational efficiency, contributing positively to the overall financial results for Laurus Labs Ltd in Q3FY25.
